|
English
|
正體中文
|
简体中文
|
2817097
|
|
???header.visitor??? :
27689767
???header.onlineuser??? :
591
???header.sponsordeclaration???
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"ottesen l h"???jsp.browse.items-by-author.description???
Showing items 1-2 of 2 (1 Page(s) Totally) 1 View [10|25|50] records per page
臺大學術典藏 |
2021-07-03T03:33:48Z |
A phase I/II multicenter study of single-agent foretinib as first-line therapy in patients with advanced hepatocellular carcinoma
|
Yau T.C.C.; Lencioni R.; Sukeepaisarnjaroen W.; Chao Y.; Yen C.-J.; Lausoontornsiri W.; PEI-JER CHEN; Sanpajit T.; Camp A.; Cox D.S.; Gagnon R.C.; Liu Y.; Raffensperger K.E.; Kulkarni D.A.; Kallender H.; Ottesen L.H.; Poon R.T.P.; Bottaro D.P. |
國立成功大學 |
2012-03 |
A PHASE I/II STUDY OF FORETINIB, AN ORAL MULTIKINASE INHIBITOR TARGETING MET, RON, AXL, TIE-2 AND VEGFR IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
|
Yau, T.; Yen, C. -J.; Chen, P. -J.; Chau, Y.; Lencioni, R.; Kallender, H.; Ottesen, L. H.; Poon, R. T. -P. |
Showing items 1-2 of 2 (1 Page(s) Totally) 1 View [10|25|50] records per page
|